drugset / Trial / NCT00349453
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine
Timeline
- Start
- 2005-03
- Primary completion
- 2011-05
- Completion
- 2011-05
Publications
- Results Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol. 1998 Jun;101(3):413-5. doi: 10.1046/j.1365-2141.1998.00725.x.
- Results Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol. 1990 Dec;76(4):550-3. doi: 10.1111/j.1365-2141.1990.tb07915.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferiprone | Small molecule | 50 mg/kg | Oral |
| Subject | Deferiprone | Small molecule | 75 mg/kg | Oral |
| Subject | Deferiprone | Small molecule | 100 mg/kg | Oral |
| Subject | Deferoxamine | Other / unclassified | 35 mg/kg | Subcutaneous |
| Subject | Deferoxamine | Other / unclassified | 50 mg/kg | Subcutaneous |